Here is a brief preview of this blast: Novo hosted its 2026 Capital Markets Day and provided updates on the strategic direction of the company across key commercial and R&D activities (view slides). While The Street and media sentiment seemed to be unduly negative on Novo’s direction (as evidenced by the -8% drop in the stock price), it appears the ongoing strong Wegovy pill launch and impending cagrisema launch should position the company to meet its operational targets in the next 3-5 years. However, the company may be challenged in the longer term, particularly as semaglutide approaches broader LOE. Below, FENIX provides details and insights from the event in Part 1 of 2. Part 2 will cover the importance of manufacturing and commercial execution with reflections from our May 2025 Obesity Spotlight on Novo Nordisk.

About The Author

Matthew Maryniak

|

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.